Drug maker Omeros Corporation (NASDAQ:OMER) delivered solid results for its earnings report for the first quarter of the year 2017. In reaction, Maxim analyst Jason …
Days are becoming tough for Gilead Sciences, Inc. (NASDAQ:GILD) as it recently released its 1Q17 earnings report.
Maxim analyst Jason Kolbert was out with a research note on Sophiris Bio Inc (NASDAQ:SPHS), following the company’s fourth-quarter financial results and update on its …
Maxim analyst Jason McCarthy comments on Mast Therapeutics Inc (NYSEMKT:MSTX) ahead of EPIC study data for the investigation of Sickle Cell Disease (SCD), …
In a research report released today, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics (NASDAQ:JUNO), with a price target …
Analyst Jason McCarthy of Maxim Group maintained a Buy rating for Galena Biopharma Inc (NASDAQ:GALE), but decreased his price target to $2, marking a 340% increase …
Healthcare analysts explain their bullish views on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and OraSure Technologies, Inc.
Maxim’s healthcare analyst Jason Kolbert weighed in today on two names in his coverage universe, Anavex Life Sciences Corp. (NASDAQ:AVXL) and Pluristem Therapeutics Inc.
While Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Gilead Sciences, Inc. (NASDAQ:GILD) remain biotech giants, they are no longer the fan-favorites they used to …
There’s good news all around as Exelixis, Inc. (NASDAQ:EXEL) releases promising data in an attempt to expand the indication of one of its …